USFDA19 Jun 2026, 09:20 pm
Aurobindo Pharma Subsidiary Completes US FDA PAI with 5 Observations
AI Summary
Aurobindo Pharma Ltd announced the completion of a US FDA Pre-Approval Inspection (PAI) at its 100% stepdown subsidiary, Eugia Steriles Private Limited, located in Andhra Pradesh. The inspection, which took place from June 10 to June 19, 2026, concluded with 5 observations. The company stated that it will respond to these observations within the stipulated time and is committed to maintaining high manufacturing standards. No immediate financial or operational impact is anticipated.
Key Highlights
- US FDA PAI completed at Eugia Steriles Private Limited.
- Inspection resulted in 5 observations.
- Company to respond within the stipulated timeframe.
- No immediate financial or operational impact reported.
Price Impact
More from AUROPHARMA